secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK:        0000882796
Form:       8-K
Filed at:   2025-11-03T23:59:59+00:00
Accession:  0001171843-25-006881
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioCryst Q3 ORLADEYO rev $159.1M (+37%); raises FY guidance; agrees to acquire Astria
--------------------------------------------------------------------------------

- ORLADEYO net rev Q3 $159.1M (+37% yoy); total rev $159.4M (+36%); non-GAAP op profit $51.7M (+107%).
- Net income $12.9M ($0.06) vs net loss $14.0M ($0.07 loss) prior year; non-GAAP net income $35.6M ($0.17).
- FY 2025 ORLADEYO rev guidance raised to $590-600M; non-GAAP op expense lowered to $430-440M; on track for positive cash flow.
- Sale of European ORLADEYO business closed; proceeds used to retire remaining $198.7M Pharmakon term debt; pro forma cash $294M.
- Definitive agreement to acquire Astria Therapeutics (navenibart Phase 3 HAE); expected close Q1 2026; Ron Dullinger named CCO effective Jan 1, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882796/000117184325006881/0001171843-25-006881-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882796/000117184325006881/f8k_110325.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-006881

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer